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Abstract
Background: Cardiac myxomas are the most frequently encountered benign intracardiac
tumors, that, if left untreated, are inexorably progressive and potentially fatal. Patients with
cardiac myxoma can be treated only by surgical removal. This study summarizes our experien-
ce over 22 years with these tumors.
Methods: Fifty seven patients (M/F: 14/43, age: 57.9 ± 14.6 years) with cardiac myxomas
underwent surgical resection at our institution. There were 82.4% left atrial myxomas, 14.0%
right atrial myxomas, 3.6% biatrial myxomas. The duration of symptoms prior to surgery
ranged from 6 to 1,373 days (median 96 days). The surgical approach comprised complete
wide excision. The diagnostic methods, incidence of thromboembolic complications, valve
degeneration, surgical repair techniques, recurrence and re-operation were reviewed and the
Kaplan-Meier survival curve was calculated.
Results: There were no in-hospital deaths. Hospital stay amounted to a mean of 13.7 ± 6.9 days.
Late follow-up was available for 54 (94.7%) patients for a median 7.5 years after surgery
(23 days to 21.4 years). Fifty two patients are alive, while five patients had died after a mean
interval of 6.3 years. Cause of death was cardiac in 40% of the patients (n = 2) and non-
-cardiac in the other 60% (n = 3).
Conclusions: Surgical excision of cardiac myxoma carries a low operative risk and gives
excellent short-term and long-term results. Surgical excision of the tumor appears to be cura-
tive, with few recurrences at long-term follow-up. After diagnosis, surgery should be performed
urgently, in order to prevent complications such as embolic events or obstruction of the
mitral orifice. Follow-up examination, including echocardiography, should be performed
regularly.(Cardiol J 2009; 16, 5: 447–454)
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Introduction
Cardiac myxomas can occur at any age, with
two peaks in the third and sixth decade of life, most
frequently observed in women [1–6]. They arise
from the endocardial tissue. Between 75 and 83%
of cardiac myxomas are located in the left atrium,
10–18% are located in the right atrium where they
often show a predilection area close to the oval fos-
sa. Morphologically they commonly present with
a pedicle 1–2 cm long determining the mobility of
the tumor. Tumor prolapse through the mitral or
tricuspid valve can lead to destruction of the valve
or the annulus [7].
Myxomas are less frequently seen in the ven-
tricles, there again showing a preference for the
right side [1, 2, 4, 5, 8, 9]. More than 95% of atrial
myxomas appear solitary, but a multifocal intracar-
diac growth is possible [5, 9, 10]. Most of these
myxomas show a pedicle. Solid tumors are ovoid-
round, elastic and smooth, whereas papillary tumors
are lobulated and gelatinous and are more likely to
embolize to the cerebral and other peripheral ves-
sels [2, 3, 5, 7, 11]. The average size is about
5–6 cm with an average weight of 46 g. The rate of
growth is not exactly known [7, 12, 13].
Relating to histology they show a stroma con-
taining few cells but plenty of mucopolysaccharides,
often with peripheral hemorrhage and necrosis. On
rare occasions, calcifications can be seen [3, 5]. In
the past, immunohistochemical and histological
studies classified benign cardiac myxomas as real
neoplasms that develop from embryonic pluripotent
mesenchymal stem cells. These undifferentiated
cells can transform and proliferate into tumor cells
[5, 14]. An explanation for the preferential tumor
localisation at the oval fossa is based on the thesis
that the interatrial septum is the last structure de-
veloping from fetal mesenchyma, containing the
most immature tissue.
The histogenesis of cardiac myxomas has been
a subject of controversy. Although they are histo-
logically classified as benign, they show biological-
ly malignant symptoms. In up to one quarter of op-
erated patients. local recurrence can be seen, some-
times associated with sporadic locally invasive
growth [15].
Often, the first manifestation of intracardiac
tumors is embolization into cerebral and peripher-
al vessels. A tumor-associated embolization can be
detected in 30–60% of patients with a localisation
of the myxoma in the left heart. Sometimes histopa-
thology of an embolus can lead to diagnosis of a pri-
mary heart tumor [2, 4, 5, 16–19].
Embolizations can be caused by blood clots
adherent to the tumor or tumor fragments. Frag-
ments from the right heart can cause inflammation
of the pleura with consecutive pleural effusion, pul-
monary hypertension or pulmonary embolism [4, 5,
18, 20]. Fragments from the left heart can cause
emboli in almost any organ, but are most frequent-
ly seen in the brain, kidneys, lower extremities or
the aorto-iliacal region [2, 21, 22]. Especially neu-
rological symptoms are frequently seen in young
patients, i.e. transient ischemic attack, stroke, spi-
nal or retinal infarction [22, 23]. Another dramatic
appearance is the embolization into the coronary
arteries [2]. Multiple organic emboli can include
many organs; differential diagnosis must include
systemic vascular diseases and bacterial endocar-
ditis, especially in the absence of typical symptoms
of obstruction or common tumor symptoms [11].
Methods
All patients undergoing cardiac myxoma exci-
sion at the Department of Cardiothoracic and Vas-
cular Surgery, Johannes Gutenberg-University,
Mainz, Germany, from January 1985 to December
2008 were identified from a retrospective chart re-
view. This study includes preoperative, short- and
long-term follow-up data. Telephone interviews by
standard questionnaire with all living patients were
taken, with the patients’ general practitioner or
specialist consulted for long-term follow up data.
The study was approved by the local bioethical
committee and all patients gave their informed consent.
For descriptive presentation of the results,
nominal variables were evaluated as absolute and
percentage figures, quantitative and ordinal varia-
bles were presented as mean, median, minimum
and maximum. Relations between categorical vari-
ables were investigated with contingency tables
and c2 test. Post-operative survival was determined
by Kaplan-Meier procedure. All tests were used
for descriptive data analyses. A p-value < 0.05
was considered statistically significant.
Results
Eighty nine patients with primary or second-
ary heart tumor were operated in the Department
of Cardiothoracic and Vascular Surgery at Johannes
Gutenberg-University, Mainz, Germany, between
January 1985 and December 2008. Figure 1 shows the
fragmentation of the histological subtypes of all
cardiac tumors. In our study, we focus on the pa-
tients with cardiac myxomas (n = 57) (Table 1).
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For cardiac strength and congestive heart fail-
ure (CHF) the New York Heart Association (NYHA)
classification was used. Twenty seven (47%) pa-
tients were NYHA I, 18 (32%) patients NYHA II,
10 (17.5%) patients NYHA III, and two (3.5%) pa-
tients NYHA IV.
In 27 patients (47.5%) their specific symptoms
did not change their quality of life; 20 patients
(35%) felt a reduction of quality of life; and 10 pa-
tients (17.5%) complained of a substantial loss of
quality of life, even their ability to handle every-
day life.
Electrocardiography was performed in every
patient; 34 patients (59.6%) showed a sinus rhythm,
seven (12.3%) patients each showed multiple
atrial and ventricular extra systoles, 16 patients
(28.1%) showed continuous arrhythmia.
In 19 (82.6%) of 23 arrhythmic patients, the
myxoma was located in the left atrium, in two pa-
tients (8.7%) it was located in the left and right atri-
um, and in two patients (8.7%) it was located in the
right atrium.
Coronary angiography was performed in
35 patients (61.4%) and five cases of coronary
artery disease needing surgery were detected.
Transthoracic echocardiography was employed in
57 patients, in all cases (100%) the estimated diag-
nosis could be verified. In this investigation
47 (82.4%) of the tumors were located in the left
atrium, eight (14.0%) in the right atrium and in two
(3.6%) the tumor was located both in the left and
right atrium. Additionally to these findings, a tumor
prolapse into the adjoining cavity of the heart could
be observed in 12 cases (21.0%). In addition, a dis-
turbance of intracardiac blood flow was observed in
six patients (10.5%), a mitral valve disturbance in
two patients (3.5%), and anterior wall hypokinesis
in one patient (1.7%). Additionally, computerized
tomography (CT scan) and also magnetic resonance
imaging (MRI) of the thorax were carried out in four
cases each. These additional diagnostic imaging
techniques confirmed the findings of the echocar-
diography. In one patient the pre-operative diagno-
sis was confirmed by biopsy of a myxoma located
in the right atrium.
The surgical excision of the tumors was per-
formed through median sternotomy with cardio-
pulmonary bypass in cardioplegic arrest. The mean
stay in intensive care unit was 3.4 days (minimum:
1 day, maximum: 13 days).
Forty four (77.2%) cases of tumor excision were
operated electively, nine (15.8%) cases were classi-
fied as urgent, and four (7.0%) cases were classified
as emergency due to life-threatening symptoms.
In 55 (96.5%) patients, a complete tumor exci-
sion was performed, two (3.5%) patients required
a second look resection for complete wide excision.
A right atrial and transseptal surgical approach was
used for tumor location in the left atrium, a right
atriotomy only for tumor location in the right atri-
um. Additionally, five patients required a coronary
artery bypass grafting operation (two single, and
three triple).
Intraoperatively, in one patient the tumor was
broadly based including the whole atrial septum and
the upper wall of the left atrium. The upper wall was
reconstructed with an autologous pericardial patch,
the intraatrial septum with a Dacron patch.
One patient showed a right atrial myxoma with
a transseptal growth into the left atrium. A complete
wide excision was accomplished; the septum was
repaired with a Dacron patch.
A local recurrence of a left atrial myxoma oc-
curred one year after primary operation and includ-
ed the left atrial upper wall, the atrial septum, and
both mitral valve leaflets.
Figure 1. The fragmentation of the histological subtypes
of all cardiac tumors (n = 89).
Table 1. Clinical characteristics of the study
population.
Patients 57
Age at operation 57.9 ± 14 years
Sex (males/females) 14/43
Duration of symptoms 6–1,373 days
prior to surgery  (median 96 days)
Coronary angiography 35
Coronary surgery 5
Operation electively 44
Operation urgent 9
Operation emergency 4
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During a second look operation, a complete
wide excision was performed including the whole
atrial septum, left atrial upper wall and both mitral
valve leaflets. The mitral valve was replaced with
a mechanical valve. For reconstruction of the left
atrial upper wall a free pericardial patch was used,
for the atrial septum a Dacron patch was used, and
for reconstruction of right atrial geometry an auto-
logous pericardial patch was used.
Intraoperative complications were caused by
prolonged bleeding from the left atrial upper wall
in one patient, and prolonged cardiopulmonary by-
pass caused by arrhythmia in four patients (atrial
fibrillation n = 1, atrio-ventricular block n = 3). No
other complications were seen.
In the early post-operative phase there were
no deaths. Early complications occurred from first
post-operative day up to the tenth postoperative day
(mean: 2.4 days). Twenty six patients (46%) showed
no complications. The most common complication
was continuous arrhythmia with atrial fibrillation.
Ten of 34 patients who had shown sinus rhythm
prior to operation presented with arrhythmia post-
operatively. Ten of 23 patients who had shown ar-
rhythmia prior to operation presented with a sinus
rhythm post-operatively.
Further post-operative complications com-
prised one case each of pericardial effusion, stroke,
myocardial infarction, pulmonary embolism, and
two cases of unilateral pleural effusion. One patient
developed a myocardial infarction on the first post-
operative day with bilateral pleural effusion, con-
secutive continuous arrhythmia and subileus. An-
other patient had to undergo re-thoracotomy be-
cause of retrosternal bleeding.
The smallest tumor size was 1.5 × 1.7 × 0.5 cm,
the largest 10.5 × 8.0 × 6.0 cm. The average size
was 5–6 cm in diameter. The mean volume was
57.7 cm3 (minimum: 1.2 cm3, maximum: 504 cm3,
median: 134.0 cm3). In our group of patients, in
47 cases (82.4%) the myxomas were located in the left
atrium, in eight (14%) cases they were located in
the right atrium, in two (3.6%) cases tumor growth
was seen in both the left and the right atrium. Cor-
rect tumor localisation could be determined pre-op-
eratively in 41 cases (71.9%), being the left atrium
in all cases. In the others the pre-operative deter-
mination of tumor localisation was incorrect.
The outer appearance was ovoid-round with
a firm and smooth surface in 28 (49.1%) cases.
Twenty six (45.6%) myxomas were lobulated or
polyploid-villous and gelatinous. Three (5.3%) tu-
mors could not be classified. Thirteen myxomas
were described as pedunculated. There was no sig-
nificant difference between ovoid-round and poly-
ploid-villous myxomas concerning embolic events
or symptoms caused by hemodynamic disorders re-
spectively.
We have complete follow-up of 54 (94.7%) out
of 57 patients. The mean follow-up time was
7.5 years (minimum: 23 days, maximum: 21.4 ye-
ars). Five patients (9.3%) died after an average
of 6.3 post-operative years (minimum: 2 months,
maximum: 16.6 years, median: 8.7 years). According
to Kaplan-Meier, the mean survival was 15.5 ye-
ars with a maximum follow-up time of 17.4 years.
Two patients died of CHF, one patient died
from pulmonary metastases of breast cancer, and
one patient died from pneumonia. One other patient
died from chronic alcoholism. In none of the patients
was a post-mortem examination performed for ex-
clusion of local tumor recurrence.
During follow-up, 13 patients (25.9%) improved
by 1 step in NYHA classification, five patients
(9.1%) by 2 steps, and two patients (3.6%) improved
by 3 steps. Within NYHA I and II there was no post-
operative improvement of cardiac output in
25 (45.2%) patients. Eight patients (14.4%) worsened
by 1 NYHA step, whereas one patient (1.8%) wors-
ened by 2 steps (Fig. 2).
Almost all patients were seen for regular
echocardiography at least once a year. With the
exception of one case there was no post-operative
recurrence of disease. During follow-up, 11 patients
received antiarrhythmic medication, two patients
underwent sinus ablation, and in one case a pace-
maker had to be implanted.
Eleven years after surgery, one patient had
a stroke due to continuous arrhythmia.
Discussion
From a pathologic-anatomic point of view one
distinguishes primarily benign, primarily malignant
Figure 2. Post-operative changes in New York Heart
Association classification (n = 54).
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and secondarily malignant heart tumors. From 75%
to 80% of all heart tumors in adults are primarily
benign. Despite the fact that from a pathologic-
-anatomic point of view only half of all benign heart
neoplasms are myxomas [1, 3, 4, 16, 24, 25], in most
surgical series, as well as in our study, myxomas
are actually the most common benign primary heart
tumors. One assumes that other benign tumors
cause less cardiac symptoms, and are therefore less
frequently discovered [24, 25]. In accordance with
the literature we found myxomas more often in fe-
males [6]. Most patients were aged over 50 years,
the average being 58.
The macroscopic structure of myxomas is
ovoid-round with a firm and smooth surface or lob-
ulated respectively polypoid-villous and gelatinous.
The latter are more likely to cause embolic events
[2, 3, 5, 7, 11]. In our study 28 myxomas (49.1%)
showed a soft and lobulated surface, 26 myxomas
(45.6%) were firm-elastic and smooth. The average
size was 5–6 cm in diameter, as in previous studies
(Fig. 3) [12, 13]. Most of the tumors are located in
the left atrium at the interatrial septum close to the
oval fossa, being attached to a 1–2 cm pedicle de-
termining the motility of the tumor. The second
most common location of myxomas is the right atri-
um [1, 2, 4, 5, 8–10, 16, 24–26]. In our study, tumor
location was the left atrium in 47 (82.4%) cases of
myxoma, in eight cases (14.0%) tumor location was
the right atrium, and in two (3.6%) cases, tumor
location was both the left and the right atrium.
Patients often present with a classic triad of
symptoms: heart failure due to obstruction, stroke
due to embolism, and constitutional, rheumatolo-
gic symptoms thought to be due to tumor secretion
of cytokines and interleukin-6. A pedunculated tu-
mor can result in obstruction of the mitral orifice,
inlet or outlet obstruction, or compression of a ven-
tricle and ensuing CHF, syncopes, or shock. Myxo-
mas obstructing the left atrium can lead to pulmo-
nary-venous congestion or incompetence or sten-
osis of the cardiac valves [4, 5, 19, 27–29].
The size, morphology and consistency (such as
length of the pedicle of the tumors) influence the
severity of clinical symptoms [7, 17].
Atrial fibrillation is the most common arrhyth-
mia seen with cardiac tumors. In accordance with our
results, it can be observed in 15% of patients with
left atrial myxoma [10, 11]. Arrhythmia can be due
to tumor infiltration into the conduction system [10].
Myxomas are often diagnosed after an incident
of cerebral, coronary or peripheral embolism. From
30% to 60% of the patients with myxoma localisa-
tion in the left heart show systemic embolization
[2, 4, 5, 16–19]. In our study 28.6% of the patients
had a history of cerebral embolism, two patients had
a history of pulmonary embolism. Polypoid-villous
(papillary) myxomas had a more frequent history of
embolization than myxomas with a smooth surface
[5, 7]. One possible explanation is that papillary
myxomas are more liable to fragmentation, erosion
and embolism. Moreover, predilection for throm-
bus growth is given on a rough surface. In this re-
spect, our study did not show any statistically sig-
nificant differences.
Patients often present with common symptoms
like loss of weight, fatigue, night sweat, fever and
rheumatologic symptoms like arthralgia and morn-
ing stiffness [2, 5]. Some authors saw a correlation
between tumor size and frequency of common
symptoms [7, 30]. Our data did not show any sta-
tistically significant correlation.
For primary diagnosis, echocardiography is of
great importance. One can identify size, motility and
localisation of cardiac tumors. Additionally, hemo-
dynamic effects can be seen by doppler-ultrasonog-
raphy [28]. In all of our patients cardiac myxomas
were diagnosed by echocardiography. Correspond-
ing to Dein et al. [24] and Miralles et al. [25] infor-
mation from echocardiography suffices as an indi-
cation for operation, and is a non-invasive, inexpen-
sive investigation for follow-up.
CT-scan and MRI detect heart tumors larger
than 0.5–1 cm in diameter. The advantage of these
methods is complete imaging of the surrounding
Figure 3. Myxoma.
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anatomical structures [31, 32]. In our study,
CT-scan or MRI was performed on eight patients
with uncertain results in echocardiography.
Coronary angiography is not mandatory in pri-
mary heart tumor patients, but it is recommended
in patients aged over 40 with risk factors for coro-
nary heart disease [5, 11, 17, 18]. In our study coro-
nary angiography was performed in 35 patients
(61.4%); five patients (5.2%) had hemodynamically
relevant stenoses and underwent surgical myocar-
dial revascularisation.
In some cases the diagnostic method was CT-
-scan-guided fine-needle-aspiration or transvenous
catheter-biopsy [18, 33]. With uncertain results
concerning malignant heart tumors, a histopatho-
logical investigation of CT-guided aspiration of pleu-
ral effusion can be performed.
Since Craaford [34] performed the first opera-
tion on a patient with left atrial myxoma in 1954,
operative techniques have developed, including
minimally invasive surgery [19, 26, 35]. An endo-
scopic approach can be an alternative to the stand-
ard median sternotomy. First choice treatment to-
day is wide excision under cadiopulmonary bypass.
All cardiac myxomas in our study were operated in
this way. The operation should be completed swiftly
after diagnosis to prevent thrombo-embolic events
[2, 36]. The mean time between diagnosis and sur-
gery in our patients was 4.3 days.
The standard surgical approach is via median
sternotomy. In special circumstances anterolate-
ral thoracotomy or port access can be used instead
[2, 4, 5, 16, 17, 19, 24–26, 35, 37, 38]. In our study,
median sternotomy was used exclusively.
The individual surgical technique depends on
tumor size, localisation and extension. Surgical ap-
proach to left atrial tumors can be gained by right-
-atrial and transseptal incision, biatrial incision or
directly by left atrial incision [2, 11, 16, 20, 24–26,
29, 35, 37, 39]. In our study left atrial access was
always realized by right-atrial incision followed by
transseptal incision. In cases of right atrial myxo-
mas, only right atrial incision was performed. Some
authors demand a careful inspection of every car-
diac cavity [16, 39]. For this reason, right atrial in-
cision followed by transseptal approach is recom-
mended for left atrial tumors.
For surgical therapy of cardiac myxomas, tu-
mor excision has to be realized with a tumor free
safety margin to prevent recurrence of disease. Left
atrial myxomas located at the septum require a wide
excision, followed by direct closure of the septum
or, preferably, with a pericardium, Goretex (PTFE)
or Dacron patch [2, 17].
In the current study 47 (82.5%) patients under-
went septum surgery; direct closure of the septum
could only be performed in ten (17.5%) patients.
Under difficult anatomical circumstances,
caused by localisation and size of the tumor, stand-
ard excision can be impossible. A case report by
Scheld et al. [40] described the excision of the heart
followed by auto-transplantation for successful re-
section of a left atrial myxoma. Despite this, a com-
plete excision of benign tumors can be impossible in
some cases. In one patient, surgical excision of the
tumor was incomplete due to tumor extension; local
recurrence of disease, including affection of the upper
wall and the septum of the left atrium as well as both
mitral valve leaflets was seen one year after prima-
ry surgery. Second look surgery including wide ex-
cision of all those structures was performed; recon-
struction of the left atrium by pericardial and Dacron-
-patches followed as well as mechanical mitral valve
replacement.
Common post-operative complications in the
literature are: effusion of the pericardium and the
pleura, osteomyelitis of the sternum, pneumonia,
maladaption of circulation after reconstruction, and
arrhythmia [27, 38, 41]. Bateman et al. [41] describe
atrial fibrillation as the most common arrhythmia, fol-
lowed by atrial flutter. Some cases of bradycardiac
arrhythmias and consecutive pacemaker implanta-
tions are described [38]. Twenty three (40%) pa-
tients in our group developed arrhythmia post-
-operatively.
Very good early post-operative results in our
study correspond to those of excision of cardiac
myxoma in the literature. The surgical mortality is
given as 1 to 4.3% [2, 4, 9, 11, 13, 16, 17, 37]. In our
study we had intraoperative deaths.
The long-term prognosis after cardiac myxo-
ma surgery is excellent, so long as there is no irre-
versible secondary damage, i.e. tumor-infiltration
of cardiac valve or embolic events. If surgery is
performed at an early stage, a cure of the disease
without disabilities is possible [1, 2, 13, 17, 39, 41].
In our study’s long-term follow-up, mean survival
time was 8.35 years. Two cases of death were most
likely due to CHF in old age. Further information
was not documented.
Several authors mention recurrence of disease
in myxoma patients [2, 9, 17, 42, 43]. McCarthy et
al. [9] divided cardiac myxomas into three catego-
ries of clinical appearance, and defined their risk of
recurrence. The most common subtype is the spo-
radic myxoma, the average patient is older than
50 years, the tumor is usually unilocular, and the
estimated risk of recurrence is less than 1%.
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The next subtype is defined as a complex
myxoma; these tumors are associated with derma-
tosis, dermal myxomas, myxoid fibroadenomas of
the breast, Cushing’s disease, pituitary adenoma,
and rarely seen testicular tumors. In these cases,
the risk of recurrence is about 20%.
Finally, there is a so-called hereditary cardiac
myxoma. Most of these patients are young and have
a positive family history. These myxomas show
traits similar to complex myxomas. Risk of recur-
rence is about 10%. To lower the rate of recurrence,
some authors demand wide excision of atrial myxo-
mas including the pedunculated base as well as the
attachment insertion in the atrial septum [2, 13].
Conclusions
1. Nowadays surgical excision of cardiac myxo-
mas on cardiopulmonary bypass is both a sta-
te-of-the-art and low risk procedure.
2. After diagnosis, surgery should be performed
quickly, in order to prevent complications such
as embolic events or obstruction of the mitral
orifice.
3. Follow-up examination including echocardio-
graphy should be performed regularly.
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